IP Library Assignment 064889/0459
Patent Assignment
Reel/Frame 064889/0459

Corrective Assignment to Correct the Assignee Name from Tisento Therapeutics, Inc. to Tisento Therapeutics Inc. Previously Recorded on Reel 064792 Frame 0500. Assignor(S) Hereby Confirms the Assignment.

Recorded: 2023-09-13 Pages: 15
Assignor
CYCLERION THERAPEUTICS, INC.
Executed: 2023-07-28
Assignee
TISENTO THERAPEUTICS INC.
245 FIRST STREET, RIVERVIEW II, 18TH FLOOR, CAMBRIDGE, MASSACHUSETTS, 02142
Covered Properties (45)
Sgc Stimulators
Treatment of Cns Diseases with Sgc Stimulators
Process for Preparing Soluble Guanylate Cyclase Stimulators
Crystalline Forms of an Sgc Stimulator
Use of Sgc Stimulators for the Treatment of Mitochonrial Disorders
Deuterated Sgc Stimulators
Treatment of Cognitive Impairment with a Cns-Penetrant Sgc Stimulator
Treatment of Cns Diseases with Sgc Stimulators
Sgc Stimulators
Treatment of Mitochondrial Diseases with a Cns-Penetrant Sgc Stimulator
Treatment of Cognitive Impairment Associated with Schizophrenia (Cias) with a Cns-Penetrant Sgc Stimulator in Combination with Antipsychotics
sGC STIMULATORS
Application: 15/693,758 →
Publication: US 2018/0065971
Sgc Stimulators
Application: 16/273,557 →
Publication: US 2019/0248794
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
Application: 16/348,359 →
Publication: US 2019/0343813
Process for Preparing Soluble Guanylate Cyclase Stimulators
Application: 16/976,249 →
Publication: US 2021/0032254
CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS
Application: 16/976,430 →
Publication: US 2021/0115050
sGC STIMULATORS
Application: 17/112,351 →
Publication: US 2021/0087198
USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
Application: 17/258,913 →
Publication: US 2021/0177846
sGC STIMULATORS
Application: 17/485,892 →
Publication: US 2022/0009937
DEUTERATED sGC STIMULATORS
Application: 17/913,273 →
Publication: US 2023/0130739
CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS
Application: 17/954,713 →
Publication: US 2023/0095799
Substituted Amidrazones as Intermediates in the Process for Preparing Soluble Guanylate Cyclase Stimulators
Application: 17/954,725 →
Publication: US 2023/0128639
TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Application: 18/031,371 →
Publication: US 2023/0372335
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
Application: 18/196,826 →
Publication: US 2023/0381153
sGC STIMULATORS
Application: 62/382,942 →
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
Application: 62/419,059 →
sGC STIMULATORS
Application: 62/423,445 →
sGC STIMULATORS
Application: 62/468,598 →
sGC STIMULATORS
Application: 62/482,486 →
Process for Preparing Soluble Guanylate Cyclase Stimulators
Application: 62/639,642 →
CRYSTALLINE FORMS OF AN sGC STIMULATOR
Application: 62/639,846 →
Use of Sgc Stimulators for the Treatment of Mitochonrial Disorders
Application: 62/696,582 →
USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
Application: 62/697,671 →
DEUTERATED sGC STIMULATORS
Application: 63/000,040 →
TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Application: 63/090,849 →
Treatment of Cognitive Impairment with a Cns-Penetrant Sgc Stimulator
Application: 63/135,797 →
sGC STIMULATORS
Application: 63/177,020 →
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
Application: 63/177,023 →
sGC STIMULATORS
Application: 63/229,248 →
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
Application: 63/229,251 →
TREATMENT OF MITOCHONDRIAL DISEASES WITH A CNS-PENETRANT sGC STIMULATOR
Application: 63/350,708 →
TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) WITH A CNS-PENETRANT sGC STIMULATOR IN COMBINATION WITH ANTIPSYCHOTICS
Application: 63/392,643 →
TREATMENT OF MITOCHONDRIAL DISEASES WITH A CNS-PENETRANT sGC STIMULATOR
Application: 63/410,829 →
Treatment of Mitochondrial Diseases with Sgc Stimulators
Application: 63/417,120 →
sGC STIMULATORS
Application: 63/417,180 →
Related Assignments (13)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 10, 2018
From: RENNIE, GLEN ROBERT; IYENGAR, RAJESH R.; LEE, THOMAS WAI-HO; NAKAI, TAKASHI
To: IRONWOOD PHARMACEUTICALS, INC.
Reel/Frame 045766/0135 →
Assignment of Assignor's Interest Apr 10, 2019
From: IRONWOOD PHARMACEUTICALS, INC.
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 048853/0001 →
Assignment of Assignor's Interest Apr 23, 2019
From: RENNIE, GLEN ROBERT; IYENGAR, RAJESH R.; LEE, THOMAS WAI-HO; NAKAI, TAKASHI
To: IRONWOOD PHARMACEUTICALS, INC.
Reel/Frame 048969/0569 →
Assignment of Assignor's Interest Oct 3, 2019
From: HADCOCK, JOHN R.
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 050609/0426 →
Assignment of Assignor's Interest Nov 18, 2019
From: JUNG, JOON; LEE, THOMAS WAI-HO; IYENGAR, RAJESH R.; PERL, NICHOLAS ROBERT
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 051036/0795 →
Assignment of Assignor's Interest Oct 28, 2020
From: STORZ, THOMAS
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 054199/0222 →
Assignment of Assignor's Interest Dec 15, 2020
From: NTI-ADDAE, KWAME W.; PRASAD, LEENA KUMARI; STORZ, THOMAS
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 054656/0239 →
Assignment of Assignor's Interest Feb 9, 2021
From: HADCOCK, JOHN R.
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 055198/0620 →
Assignment of Assignor's Interest Mar 18, 2021
From: RENNIE, GLEN ROBERT; IYENGAR, RAJESH R.; LEE, THOMAS WAI-HO; RENHOWE, PAUL ALLAN
To: IRONWOOD PHARMACEUTICALS, INC
Reel/Frame 055644/0178 →
Assignment of Assignor's Interest Mar 18, 2021
From: IRONWOOD PHARMACEUTICALS, INC.
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 055644/0220 →
Assignment of Assignor's Interest Apr 11, 2023
From: RENNIE, GLEN ROBERT; IYENGAR, RAJESH R.; LEE, THOMAS WAI-HO; RENHOWE, PAUL ALLAN
To: IRONWOOD PHARMACEUTICALS, INC.
Reel/Frame 063288/0321 →
Assignment of Assignor's Interest Apr 13, 2023
From: IRONWOOD PHARMACEUTICALS, INC.
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 063316/0835 →
Assignment of Assignor's Interest Sep 1, 2023
From: CYCLERION THERAPEUTICS, INC.
To: TISENTO THERAPEUTICS, INC.
Reel/Frame 064792/0500 →